COVID-19 reinfection casts doubt on virus immunity: study

By Patrick GALEY

The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.

© 2020 AFP

©2021 GPlusMedia Inc.

Login to comment

A study published in The Lancet Infectious Diseases journal charts the first confirmed case of COVID-19 reinfection in the United States -- the country worst hit by the pandemic -- and indicates that exposure to the virus may not guarantee future immunity.

To be completely fair that is true for every other infectious disease, from measles to ebola. In medicine nothing is 100% true all the time.

Experts said the prospect of reinfection could have a profound impact on how the world battles through the pandemic

Of course, but only if it is something that happens with a certain frequency. If you observe one reinfection for every million cases that would not have a significative impact.

Vaccines work by triggering the body's natural immune response to a certain pathogen, arming it with antibodies it to fight off future waves of infection.

But it is not at all clear how long COVID-19 antibodies last.

That is not completely true, vaccines work by stimulating the immune response, including antibodies but also other parts of the system that can protect against future exposures. Antibodies are just the easiest to examine, not the only important part.

The real importance of studying these rare reinfections is because they let us understand better the infection and hopefully identify exactly what parts of the immune reaction are the most important to avoid complications.

The authors said the U.S. patient could have been exposed to a very high dose of the virus the second time around, triggering a more acute reaction.

Alternatively, it may have been a more virulent strain of the virus.

Or the patient could have some natural susceptibility because of genetic variation, or low levels of some specific lymphocytes, or some comorbidity that was not identified the first time that lowered temporarily his immune system. As long as the reinfections are very limited it is more likely that the specific situation of the patient is responsible than a viral factor.

Another hypothesis is a mechanism known as antibody dependent enhancement -- that is, when antibodies actually make subsequent infections worse, such as with dengue fever.

Extremely unlikely, like astronomically so.

ADE depends on having serotypes of the infection, that means that antibodies against one strain are not useful against a different strain (for Dengue there are 4 serotypes, so a completely healthy person can get infected 4 times with the disease) For COVID there is only one serotype identified yet.

Also, if ADE was the cause you would observe clusters of reinfections with very severe symptoms, because people infected once would not have any protection against the different serotype of the virus and many of those reinfected people would have very severe symptoms, even if they were young adults without comorbidities, that would be like a huge red alert if it happened anywhere in the world.

However, since many cases are asymptomatic and therefore unlikely to have tested positive initially, it may be impossible to know if a given Covid-19 case is the first or second infection.

For any specific case this is true (unless specialized tests are done to search for differences in neutralization levels of the antibodies and curves of elevation on IgG and IgM), but in a community level epidemiological analysis would give very strong hints of this happening. This kind of data is relatively easier to get, so many researchers are using it to find out unusual patterns or outliers that could be of interest. So for now the possibility of reinfections being common remains very low.

"This information is key to understanding which vaccines are capable of crossing that threshold to confer individual and herd immunity," added Iwasaka, who was not involved in the study.

And also to understand how long the immunity for the natural infection lasts.

4 ( +7 / -3 )

5 cases worldwide! Appears to be a very rare event.

And also to understand how long the immunity for the natural infection lasts.

Those who recovered from the 1st SARS CoV (17 years ago) still have the memory lymphocytes that would protect them from a second attack. So far, it appears to also be the case for SARSCoV2, but its too soon to know for sure. Time will tell.

-2 ( +0 / -2 )

And trump wants a rally of 10.000.

Good on you fella, the more bigly, the better.

R I P trump

2 ( +3 / -1 )

R I P trump

R I P : Remain In Prison

1 ( +2 / -1 )

Login to leave a comment

Facebook users

Use your Facebook account to login or register with JapanToday. By doing so, you will also receive an email inviting you to receive our news alerts.

Facebook Connect

Login with your JapanToday account

User registration

Articles, Offers & Useful Resources

A mix of what's trending on our other sites